Title not available

by Claudio Jommi
Published 2015-09-01

Title not available

by Claudio Jommi, Marianna Cavazza
Published 2019-07-01

Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals

by Claudio Jommi, Marianna Cavazza
Published 2019-07-01

Title not available

by Carlo Lucioni, Claudio Jommi
Published 2019-11-01

The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

by Claudio Jommi, Roberto Ravasio
Published 2019-11-01

Value of health technologies, HTA and decisions

by Carlo Lucioni, Claudio Jommi
Published 2016-12-01

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi
Published 2018-10-01

Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi
Published 2019-03-01

Current pipelines for neglected diseases.

by Paolo di Procolo, Claudio Jommi
Published 2014-09-01

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system

by Claudio Jommi, Paolo Bruzzi, Carlotta Galeone
Published 2021-01-01

Title not available

by Carla Rognoni, Arianna Bertolani, Claudio Jommi
Published 2018-06-01

Title not available

by Claudio Jommi, MSc, Arianna Bertolani, Phd
Published 2018-04-01

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

by Carla Rognoni, Arianna Bertolani, Claudio Jommi
Published 2018-06-01

Patients’ Associations and HTA for medicines: actual and future role in Italy

by Claudio Jommi MSc, Arianna Bertolani Phd
Published 2018-04-01

Health care costs of influenza-related episodes in high income countries: A systematic review.

by Carlo Federici, Marianna Cavazza, Francesco Costa, Claudio Jommi
Published 2018-01-01

Title not available

by Claudio Jommi, Francesco S. Mennini, Pier L. Canonico, Paolo Bruzzi
Published 2016-11-01

The future of Funds for Innovative Medicines: results from a Delphi Study

by Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto
Published 2021-03-01

The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service

by Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria Paola Pedone, Walter Canonica
Published 2020-07-01

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

by Virginia Ronco, Myriam Dilecce, Elena Lanati, Pier Luigi Canonico, Claudio Jommi
Published 2021-03-01

Title not available

by Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
Published 2018-08-01